TY - JOUR
T1 - Disease-Toxicant Interactions in Parkinson’s Disease Neuropathology
AU - Kwakye, Gunnar F.
AU - McMinimy, Rachael A.
AU - Aschner, Michael
N1 - Funding Information:
GFK was supported in part by Oberlin College Office of Foundation, Government, and Corporate Grants. RAM was supported in part by Robert Rich Student Research Grant at Oberlin College. MA was supported in part by NIEHS Grants R01ES07331, R01ES10563 and R01ES020852.
Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Human disease commonly manifests as a result of complex genetic and environmental interactions. In the case of neurodegenerative diseases, such as Parkinson’s disease (PD), understanding how environmental exposures collude with genetic polymorphisms in the central nervous system to cause dysfunction is critical in order to develop better treatment strategies, therapies, and a more cohesive paradigm for future research. The intersection of genetics and the environment in disease etiology is particularly relevant in the context of their shared pathophysiological mechanisms. This review offers an integrated view of disease-toxicant interactions in PD. Particular attention is dedicated to how mutations in the genes SNCA, parkin, leucine-rich repeat kinase 2 (LRRK2) and DJ-1, as well as dysfunction of the ubiquitin proteasome system, may contribute to PD and how exposure to heavy metals, pesticides and illicit drugs may further the consequences of these mutations to exacerbate PD and PD-like disorders. Although the toxic effects induced by exposure to these environmental factors may not be the primary causes of PD, their mechanisms of action are critical for our current understanding of the neuropathologies driving PD. Elucidating how environment and genetics collude to cause pathogenesis of PD will facilitate the development of more effective treatments for the disease. Additionally, we discuss the neuroprotection exerted by estrogen and other compounds that may prevent PD and provide an overview of current treatment strategies and therapies.
AB - Human disease commonly manifests as a result of complex genetic and environmental interactions. In the case of neurodegenerative diseases, such as Parkinson’s disease (PD), understanding how environmental exposures collude with genetic polymorphisms in the central nervous system to cause dysfunction is critical in order to develop better treatment strategies, therapies, and a more cohesive paradigm for future research. The intersection of genetics and the environment in disease etiology is particularly relevant in the context of their shared pathophysiological mechanisms. This review offers an integrated view of disease-toxicant interactions in PD. Particular attention is dedicated to how mutations in the genes SNCA, parkin, leucine-rich repeat kinase 2 (LRRK2) and DJ-1, as well as dysfunction of the ubiquitin proteasome system, may contribute to PD and how exposure to heavy metals, pesticides and illicit drugs may further the consequences of these mutations to exacerbate PD and PD-like disorders. Although the toxic effects induced by exposure to these environmental factors may not be the primary causes of PD, their mechanisms of action are critical for our current understanding of the neuropathologies driving PD. Elucidating how environment and genetics collude to cause pathogenesis of PD will facilitate the development of more effective treatments for the disease. Additionally, we discuss the neuroprotection exerted by estrogen and other compounds that may prevent PD and provide an overview of current treatment strategies and therapies.
KW - Disease-toxicant interaction
KW - Estrogen
KW - Gene-environment interaction
KW - Heavy metals
KW - Illicit drugs
KW - Neurodegeneration
KW - Parkinson’s disease (PD)
KW - Pesticides
UR - http://www.scopus.com/inward/record.url?scp=84986269078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986269078&partnerID=8YFLogxK
U2 - 10.1007/s11064-016-2052-4
DO - 10.1007/s11064-016-2052-4
M3 - Article
C2 - 27613618
AN - SCOPUS:84986269078
SN - 0364-3190
VL - 42
SP - 1772
EP - 1786
JO - Neurochemical Research
JF - Neurochemical Research
IS - 6
ER -